Deedwania P C
Cardiology Section, Veterans Administration Medical Center, Fresno, CA 93703.
Postgrad Med. 1988 Mar;83(4):223-5, 228-30. doi: 10.1080/00325481.1988.11700196.
Patients with CHF are commonly encountered in clinical practice. Cardiac arrhythmias, particularly complex ventricular premature contractions, often occur in these patients. The presence of ventricular tachyarrhythmia, especially ventricular tachycardia, denotes a poor prognosis. Patients with CHF already have a limited life span, and the presence of ventricular arrhythmia further increases an already high death rate. Although previous reports failed to show any significant effect of treatment on mortality in patients with CHF, results of recent studies are encouraging. Several reports have shown that treatment with angiotensin converting enzyme inhibitors and newer antiarrhythmic agents reduces the frequency of ventricular arrhythmia and decreases mortality. It is hoped that the results of these studies will be confirmed in well-controlled, large-scale, prospective trials.
慢性心力衰竭（CHF）患者在临床实践中很常见。心律失常，尤其是复杂性室性早搏，在这些患者中经常出现。室性快速性心律失常，特别是室性心动过速的存在，预示着预后不良。CHF患者的寿命本就有限，而室性心律失常的存在进一步增加了本就很高的死亡率。尽管先前的报告未能显示治疗对CHF患者死亡率有任何显著影响，但最近的研究结果令人鼓舞。几份报告表明，使用血管紧张素转换酶抑制剂和新型抗心律失常药物进行治疗可降低室性心律失常的发生率并降低死亡率。希望这些研究结果能在严格控制的大规模前瞻性试验中得到证实。
